Skip to main content

Evidence to Improve Care

Levonorgestrel-Releasing Intrauterine System (52 mg) for Idiopathic Heavy Menstrual Bleeding


Ontario Health Technology Advisory Committee Recommendation

  • The Ontario Health Technology Advisory Committee recommends publicly funding the 52-mg levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding

Read the full OHTAC Recommendation report



Heavy menstrual bleeding can be painful, distressing and disruptive. Up to one-third of women between the ages of 15 and 55 experience heavy menstrual bleeding, and often the cause is unknown. However, treatment can reduce the symptoms and improve quality of life. Some options include medications, surgery, and a device called the levonorgestrel-releasing intrauterine system.


Health Quality Ontario Reviews the Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding

The levonorgestrel-releasing intrauterine system is a minimally invasive and reversible device that is inserted in the uterus where it releases a hormone that suppresses and thins the lining of the uterus (endometrium), which can result in a reduction in the amount of bleeding. Currently, the insertion procedure is publicly funded in Ontario but the cost of the device is not.


Levonorgestrel-Releasing Intrauterine System (52 mg) for Idiopathic Heavy Menstrual Bleeding: A Health Technology Assessment (PDF)
November 2016


Use of this site, and the interpretation of the information contained here, is subject to important terms and conditions. Use of this site and information except in accordance with these terms and conditions is expressly prohibited.


The Ministry of Health and Long-Term Care has accepted this recommendation.

The Ministry of Health and Long-Term Care has provided the following response: The Ministry provides funding for this drug product for women eligible for the Ontario Drug Benefit and is evaluating options to increase its use.




Health Technology Assessment at Health Quality Ontario

As part of our core function to promote health care supported by the best available evidence, we use established scientific methods to analyze the evidence for a wide range of health interventions, including diagnostic tests, medical devices, interventional and surgical procedures, health care programs and models of care. These analyses are informed by input from a range of individuals, including patients and clinical experts. The Ontario Health Technology Advisory Committee (OHTAC) — a committee of the Health Quality Ontario board of directors — reviews the evidence and makes recommendations about whether health care interventions should be publicly funded or not. Draft recommendations are posted on the Health Quality Ontario website for feedback. Final recommendations are approved by our board of directors and then shared with the Ministry of Health and Long-Term Care. For more detailed information, visit our Evidence to Improve Care pages.


RECEIVE NOTIFICATION OF WHEN OUR DRAFT RECOMMENDATIONS ARE OPEN FOR FEEDBACK

Sign up for our newsletter to receive monthly notifications of when draft recommendations are open for feedback

A senior couple looking at their tablet together

Let’s make our health system healthier

Join Our Patient, Family and Public Advisors Program

Patients, families and the public are central to improving health quality.


Claude Lurette and Kowsiya Vijayartnam, Health Quality Ontario Patient, Family and Caregiver Advisors Council Co-Chairs

Sign up for our newsletter

Are you passionate about quality health care for all Ontarians? Stay in-the-know about our newest programs, reports and news.

Health Quality Connect - Health Quality Ontario's newsletter - on an iPad and a cell phone